Ipilimumab vs Sars-Cov-2 Virus Spike Protein
Ipilimumab vs Sars-Cov-2 Virus Spike Protein: Overview
This comparison examines the pharmacological differences between Ipilimumab and Sars-Cov-2 Virus Spike Protein.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Sars-Cov-2 Virus Spike Protein — Vaccine component.